Unilife realigns business units and leadership team
Chairman and Chief Executive Officer Alan Shortall and President and Chief Operating Officer Dr. Ramin Mojdeh will step down from their positions with Unilife, effective immediately.
John Ryan, Senior Vice President, General Counsel and Secretary, will serve as Interim CEO.
As Interim CEO, Mr. Ryan brings more than two decades of experience in business, law and government to the role. Joining Unilife in 2014, Mr. Ryan was previously a Partner at Duane Morris LLP, a Senior Vice President and Deputy General Counsel of Aramark Corporation and an Assistant District Attorney at the Manhattan District Attorney's Office.
The Board of Directors has also appointed an Executive Leadership Team representing key operational areas of the company to work in close collaboration with Mr. Ryan and Unilife's Board of Directors.
David Hastings, Senior Vice President and Chief Financial Officer, joined Unilife in 2015 and is a veteran finance executive who was previously CFO of Incyte Corporation from 2003 to 2014. Mr. Hastings has broad public company finance experience in roles at ArQule, Inc., Genzyme (now a wholly owned subsidiary of Sanofi), and PriceWaterhouseCoopers.
Ian Hanson, Senior Vice President and General Manager of Unilife's Wearable Injector and Auto Injector business unit, joined Unilife in 2011 from Medtronic Diabetes, where he held senior leadership roles in the development and commercialization of insulin delivery devices and diabetes management systems. At Unilife, Mr. Hanson initiated and led the development of Unilife's industry-leading wearable injector platform and team.
Michael Ratigan, Senior Vice President and Chief Commercial Officer, joined Unilife in 2011 from Becton Dickinson where he was a global commercial leader for Self-Injection Systems and also led commercial efforts for Pre-Filled Syringes in the North American market.
Since joining Unilife Mr. Ratigan has led Unilife's commercial efforts, including the entry into multiple strategic collaborations with leading pharmaceutical and biopharmaceutical companies. ■